Travere Therapeutics, Inc.
TVTX
Rang in Aktien
#3625
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies... Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Aktienkurs
$49.66
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$4.68B
Veränderung (1 Tag)
-5.93%
Veränderung (1 Jahr)
81.77%
Land
US
Handel Travere Therapeutics, Inc. (TVTX)
Kategorie
Healthcare
EPS für Travere Therapeutics, Inc. (TVTX)
EPS zum June 2026 TTM: $-0.45
Laut den aktuellen Finanzberichten und dem Aktienkurs von Travere Therapeutics, Inc. beträgt das aktuelle EPS des Unternehmens (TTM) $-0.45. Am Ende des Jahres 2023 betrug das EPS $-1.50 ein Rückgang im Vergleich zu dem EPS von 2022, das $-4.37 betrug.
EPS-Verlauf von Travere Therapeutics, Inc. von 2009 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $-0.45 | -88.97% |
| 2024 | $-4.08 | 172.00% |
| 2023 | $-1.50 | -65.68% |
| 2022 | $-4.37 | 45.18% |
| 2021 | $-3.01 | -15.45% |
| 2020 | $-3.56 | 2.89% |
| 2019 | $-3.46 | 36.22% |
| 2018 | $-2.54 | 64.94% |
| 2017 | $-1.54 | 19.38% |
| 2016 | $-1.29 | -136.96% |
| 2015 | $3.49 | -178.78% |
| 2014 | $-4.43 | 86.13% |
| 2013 | $-2.38 | -99.16% |
| 2012 | $-284.40 | 142,199,900.00% |
| 2009 | 0.00 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $17.32 | -3,948.89% |
US
|
|
| $-7.98 | 1,673.33% |
US
|
|
| $-5.29 | 1,075.56% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -6,264.44% |
NL
|
